Imperial College London

Modus Therapeutics announced a fully secured rights issue of SEK 28.3 million to finance continued clinical development of sevuparin, a drug candidate for chronic kidney disease with anemia.

MAIA Biotechnology appointed two prominent hepatocellular carcinoma specialists, Dr. Claudia Fulgenzi and Dr. David J. Pinato, to its Scientific Advisory Board to guide upcoming clinical trials.

A randomized controlled trial involving 292 children across four African countries found that intravenous rehydration was as safe as oral rehydration for children with severe acute malnutrition and gastroenteritis.

P2Y12 inhibitors including ticagrelor and clopidogrel demonstrated a 23% lower risk of cardiovascular death, heart attack, or stroke compared to aspirin in patients following coronary stent placement.

Metsera will present clinical data from its completed Phase 1/2 trial of MET-097i, a fully biased, monthly, ultra-long acting GLP-1 receptor agonist, at the 85th Scientific Sessions of the American Diabetes Association.

Global rheumatoid arthritis incidence increased 13.2% from 1990 to 2021, affecting 17.9 million people worldwide by 2021, with significant regional disparities and a shift toward younger age groups.

England becomes the first country globally to implement a gonorrhoea vaccination program, targeting high-risk populations as infections reach record levels with over 85,000 cases reported in 2023.

The UK has introduced new guidance requiring sponsors to demonstrate how they will ensure diverse participant representation in clinical trials for drugs and medical devices.

UK regulatory authorities have approved AstraZeneca's Trixeo Aerosphere as the first pressurized metered-dose inhaler using a next-generation propellant with 99.9% lower Global Warming Potential than current options.

Imperial College spinout OSSTEC has raised £2.5 million to pursue US regulatory approval for its innovative 3D-printed joint replacement system that mimics bone properties.